Literature DB >> 29269441

Sputum microbiome temporal variability and dysbiosis in chronic obstructive pulmonary disease exacerbations: an analysis of the COPDMAP study.

Zhang Wang1, Richa Singh2, Bruce E Miller3, Ruth Tal-Singer3, Stephanie Van Horn4, Lynn Tomsho4, Alexander Mackay2, James P Allinson2, Adam J Webb5, Anthony J Brookes5, Leena M George6, Bethan Barker6, Umme Kolsum7, Louise E Donnelly2, Kylie Belchamber2, Peter J Barnes2, Dave Singh7, Christopher E Brightling6, Gavin C Donaldson2, Jadwiga A Wedzicha2, James R Brown1.   

Abstract

BACKGROUND: Recent studies suggest that lung microbiome dysbiosis, the disease associated disruption of the lung microbial community, might play a key role in chronic obstructive pulmonary disease (COPD) exacerbations. However, characterising temporal variability of the microbiome from large longitudinal COPD cohorts is needed to better understand this phenomenon.
METHODS: We performed a 16S ribosomal RNA survey of microbiome on 716 sputum samples collected longitudinally at baseline and exacerbations from 281 subjects with COPD at three UK clinical centres as part of the COPDMAP consortium.
RESULTS: The microbiome composition was similar among centres and between stable and exacerbations except for a small significant decrease of Veillonella at exacerbations. The abundance of Moraxella was negatively associated with bacterial alpha diversity. Microbiomes were distinct between exacerbations associated with bacteria versus eosinophilic airway inflammation. Dysbiosis at exacerbations, measured as significant within subject deviation of microbial composition relative to baseline, was present in 41% of exacerbations. Dysbiosis was associated with increased exacerbation severity indicated by a greater fall in forced expiratory volume in one second, forced vital capacity and a greater increase in CAT score, particularly in exacerbations with concurrent eosinophilic inflammation. There was a significant difference of temporal variability of microbial alpha and beta diversity among centres. The variation of beta diversity significantly decreased in those subjects with frequent historical exacerbations.
CONCLUSIONS: Microbial dysbiosis is a feature of some exacerbations and its presence, especially in concert with eosinophilic inflammation, is associated with more severe exacerbations indicated by a greater fall in lung function. TRIAL REGISTRATION NUMBER: Results, NCT01620645. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  bacterial infection; copd exacerbations; copd pathology

Mesh:

Year:  2017        PMID: 29269441     DOI: 10.1136/thoraxjnl-2017-210741

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  33 in total

1.  Multi-omic meta-analysis identifies functional signatures of airway microbiome in chronic obstructive pulmonary disease.

Authors:  Zhang Wang; Yuqiong Yang; Zhengzheng Yan; Haiyue Liu; Boxuan Chen; Zhenyu Liang; Fengyan Wang; Bruce E Miller; Ruth Tal-Singer; Xinzhu Yi; Jintian Li; Martin R Stampfli; Hongwei Zhou; Christopher E Brightling; James R Brown; Martin Wu; Rongchang Chen; Wensheng Shu
Journal:  ISME J       Date:  2020-07-27       Impact factor: 10.302

2.  Journal Club - Bronchiectasis/COPD Overlap: Syndrome Versus Treatable Trait?

Authors:  Ron Balkissoon
Journal:  Chronic Obstr Pulm Dis       Date:  2019-04

3.  The respiratory tract microbiome and its relationship to lung cancer and environmental exposures found in rural china.

Authors:  H Dean Hosgood; Emmanuel F Mongodin; Yunhu Wan; Xing Hua; Nathaniel Rothman; Wei Hu; Roel Vermeulen; Wei Jie Seow; Thomas Rohan; Jun Xu; Jihua Li; Jun He; Yunchao Huang; Kaiyun Yang; Guoping Wu; Fusheng Wei; Jianxin Shi; Amy R Sapkota; Qing Lan
Journal:  Environ Mol Mutagen       Date:  2019-05-08       Impact factor: 3.216

4.  Journal Club-- COPD Exacerbations and Gastroesophageal Reflux Disease: Why Proton Pump Inhibitor Therapy is Not Enough.

Authors:  Ron Balkissoon
Journal:  Chronic Obstr Pulm Dis       Date:  2019-10-23

Review 5.  Impact of Lung Microbiota on COPD.

Authors:  Cristina Russo; Valeria Colaianni; Giuseppe Ielo; Maria Stella Valle; Lucia Spicuzza; Lucia Malaguarnera
Journal:  Biomedicines       Date:  2022-06-06

Review 6.  The lung microbiome: progress and promise.

Authors:  Samantha A Whiteside; John E McGinniss; Ronald G Collman
Journal:  J Clin Invest       Date:  2021-08-02       Impact factor: 19.456

Review 7.  COPD and Gut-Lung Axis: How Microbiota and Host Inflammasome Influence COPD and Related Therapeutics.

Authors:  Ling Qu; Qing Cheng; Yan Wang; Hui Mu; Yunfeng Zhang
Journal:  Front Microbiol       Date:  2022-04-01       Impact factor: 6.064

8.  Anti-bacterial antibody and T cell responses in bronchiectasis are differentially associated with lung colonization and disease.

Authors:  Fathia G Jaat; Sajidah F Hasan; Audrey Perry; Sharon Cookson; Santosh Murali; John D Perry; Clare V Lanyon; Anthony De Soyza; Stephen M Todryk
Journal:  Respir Res       Date:  2018-05-30

9.  Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles.

Authors:  Michael A Ghebre; Pee Hwee Pang; Sarah Diver; Dhananjay Desai; Mona Bafadhel; Koirobi Haldar; Tatiana Kebadze; Suzanne Cohen; Paul Newbold; Laura Rapley; Joanne Woods; Paul Rugman; Ian D Pavord; Sebastian L Johnston; Michael Barer; Richard D May; Christopher E Brightling
Journal:  J Allergy Clin Immunol       Date:  2018-04-28       Impact factor: 10.793

Review 10.  Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations.

Authors:  Andrew I Ritchie; Jadwiga A Wedzicha
Journal:  Clin Chest Med       Date:  2020-09       Impact factor: 2.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.